TY - JOUR
T1 - Role of coronary computed tomography angiography (CTA) post the ISCHEMIA trial
T2 - Precision prevention based on coronary CTA-derived coronary atherosclerosis
AU - Nakanishi, Rine
AU - Osawa, Kazuhiro
AU - Kurata, Akira
AU - Miyoshi, Toru
N1 - Funding Information:
None.
Publisher Copyright:
© 2021
PY - 2022/5
Y1 - 2022/5
N2 - The International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA) trial has been recently published and suggested the importance of the selection of patients at high risk for future cardiovascular disease events and the enhancing optimal medical therapy. In the ISCHEMIA trial, coronary computed tomography angiography (CTA) was performed in most of the patients to exclude high-risk patients and those without obstructive coronary artery disease (CAD) who should not be randomized. Coronary CTA has been widely used as a non-invasive diagnostic modality to assess patients with suspected CAD. Currently, the international guidelines allow use of coronary CTA as a class I recommendation for patients with chest pain. Besides, in the numerous multicenter trials, the emerging role of coronary CTA has proven that it could soon become the standard for monitoring CAD and identifying patients at high risk of future cardiovascular events. In this review article, we summarize the current evidence on coronary CTA and the potential role of coronary CTA after the ISCHEMIA trial for patients with CAD. Risk assessment using detailed CAD data obtained non-invasively and prevention of future cardiovascular events through improved medical care will become increasingly essential for the precision treatment and prevention of CAD in patients.
AB - The International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA) trial has been recently published and suggested the importance of the selection of patients at high risk for future cardiovascular disease events and the enhancing optimal medical therapy. In the ISCHEMIA trial, coronary computed tomography angiography (CTA) was performed in most of the patients to exclude high-risk patients and those without obstructive coronary artery disease (CAD) who should not be randomized. Coronary CTA has been widely used as a non-invasive diagnostic modality to assess patients with suspected CAD. Currently, the international guidelines allow use of coronary CTA as a class I recommendation for patients with chest pain. Besides, in the numerous multicenter trials, the emerging role of coronary CTA has proven that it could soon become the standard for monitoring CAD and identifying patients at high risk of future cardiovascular events. In this review article, we summarize the current evidence on coronary CTA and the potential role of coronary CTA after the ISCHEMIA trial for patients with CAD. Risk assessment using detailed CAD data obtained non-invasively and prevention of future cardiovascular events through improved medical care will become increasingly essential for the precision treatment and prevention of CAD in patients.
KW - Coronary atherosclerosis
KW - Coronary computed tomography angiography
KW - High-risk plaque
KW - Low-attenuation plaque
KW - Precision prevention
UR - http://www.scopus.com/inward/record.url?scp=85122013050&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122013050&partnerID=8YFLogxK
U2 - 10.1016/j.jjcc.2021.12.006
DO - 10.1016/j.jjcc.2021.12.006
M3 - Review article
C2 - 34974937
AN - SCOPUS:85122013050
SN - 0914-5087
VL - 79
SP - 572
EP - 580
JO - Journal of Cardiography
JF - Journal of Cardiography
IS - 5
ER -
